Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 216  
Year : 2015  |  Volume : 14  |  Issue : 1  |  Page : 51-52

Systemic Radiopharmaceutical Agents (Sm-153) may be Dangerous in Hepatacellular Carcinoma

1 Department of Gastroenterology, School of Medicine, Ankara University, Ankara, Turkey
2 Department of Nuclear Medicine, School of Medicine, Ankara University, Ankara, Turkey

Correspondence Address:
Onur Keskin
Department of Gastroenterology, School of Medicine, Ankara University, Ibni Sina Hospital, Ankara
Login to access the Email id

DOI: 10.4103/1450-1147.150548

PMID: 25709546

Rights and Permissions

Palliation of bone metastases in hepatocellular carcinoma (HCC) is sometimes difficult. Systemic pharmaceuticals have been successfully used for the palliation of bone metastasis for many years. Safety of these agents in HCC is not known completely. We presented a male patient with decompensated liver cirrhosis with HCC. Multifocal bone metastases developed in this patient and he had refractory bone pain. We treated this patient with Sm-153 (samarium) after obtaining patient's consent. Two days after treatment, he experienced dyspnea and we detected a massive hemorrhagic pericardial effusion. He died due to this unexpected bleeding. We should use this radiopharmaceutical treatment cautiously in these cytopenic cirrhotic patients.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded211    
    Comments [Add]    

Recommend this journal